Cargando…
Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study
Background: The use of immune-modifying biological agents has markedly changed the clinical course and the management of Inflammatory bowel diseases (IBDs). Active post-marketing surveillance programs are fundamental to early recognize expected and unexpected adverse events (AEs), representing a pow...
Autores principales: | Tallarico, Martina, Palleria, Caterina, Ruffolo, Livia, Spagnuolo, Rocco, Naturale, Maria Diana, De Francesco, Adele Emanuela, De Sarro, Caterina, Romeo, Rossella, Citraro, Rita, Doldo, Patrizia, Abenavoli, Ludovico, Gallelli, Luca, Luzza, Francesco, Leo, Antonio, De Sarro, Giovambattista |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696291/ https://www.ncbi.nlm.nih.gov/pubmed/36432640 http://dx.doi.org/10.3390/pharmaceutics14112449 |
Ejemplares similares
-
Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region
por: Gagliardi, Agnese, et al.
Publicado: (2022) -
Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy
por: Leporini, Christian, et al.
Publicado: (2022) -
Pharmacovigilance in Calabria (Italy): Local experiences resonate international relevance
por: Russo, Emilio, et al.
Publicado: (2013) -
Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
por: Palleria, Caterina, et al.
Publicado: (2018) -
Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)